SOURCE: Implant Sciences

Implant Sciences

December 16, 2010 07:00 ET

Implant Sciences Announces New Sales Contracts in Japan and Singapore

Uses Include Critical Infrastructure Protection, Law Enforcement, and Corporate Security

WILMINGTON, MA--(Marketwire - December 16, 2010) -   Implant Sciences Corporation (PINKSHEETS: IMSC) (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security markets, today announced that it has signed sales contracts for its Quantum Sniffer™ QS-H150 explosives trace detector in Japan and Singapore. The Quantum Sniffer will be deployed for critical infrastructure protection at nuclear power facilities, corporate security, and law enforcement. 

Glenn Bolduc, CEO of Implant Sciences, commented, "These sales demonstrate the versatility of the Quantum Sniffer for both government and corporate applications and the increasing adoption of Implant Sciences' technology worldwide. They include orders through both existing and recently signed partners, underscoring the growing strength of our distribution channel."

About the Quantum Sniffer QS-H150

The QS-H150 Quantum Sniffer is a hand-held explosive trace detector that uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, improvised, and homemade explosives. The QS-H150 features a low-maintenance design that is self-calibrating and self-clearing, providing very high levels of operational availability.

About Implant Sciences

Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosive trace detection systems which ship to a growing number of locations domestically and internationally. For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by governments or by other law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact Information

  • Contact:

    Implant Sciences Corporation
    Company Contact:
    Glenn Bolduc
    CEO
    978-752-1700
    Email Contact

    or

    Investor Contact:
    Laurel Moody
    646-810-0608
    Email Contact